Project Grant HT94252310434
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$397K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This federal Project Grant award of $523,614.37, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research into the genetic mechanisms underlying schwannomatosis and other rare conditions. The University of Manchester, a prominent research institution in the United Kingdom, will conduct this 3-year research initiative, focusing on elucidating the disease-specific genetic factors that distinguish...
The Defense Health Agency awarded $603,000 to the Massachusetts General Hospital under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "CLINICAL AND MRI PREDICTORS OF INTERNAL NEUROFIBROMA GROWTH IN NEUROFIBROMATOSIS TYPE 1" from September 30, 2021 through September 29, 2024. This project grant will fund research at Massachusetts General Hospital to investigate clinical and MRI predictors of internal neurofibroma growth in...
The University of Minnesota will leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors under a $548,892 project grant from the Defense Health Agency. The grant was awarded on August 1, 2023 with a completion date of July 31, 2026. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through...
The University of Alabama at Birmingham will use a $148,500 Project Grant from the Defense Health Agency to support research titled "SMART-BASED REPAIR OF NF1 PRE-MRNA." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research solutions. Specifically, the university will investigate medical solutions for the battlefield by exploring RNA-based therapies to...
This $713,818 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to characterize novel patient-specific modeling systems for NF2 disease research and therapeutic testing. The project will be conducted from September 1, 2024 through August 31, 2027. The Research Institute has extensive experience delivering federal research...
The University of Minnesota was awarded a $479,946 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
The federal Project Grant award with ID HT94252410711, titled "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,568,220.00 grant, with a performance period from Sep 15, 2024 to Sep 14, 2027, was awarded to The General Hospital Corporation's Research Management Division, doing business as Massachusetts General Hospital (MGH). Through this funding, MGH will conduct...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
The U.S. Defense Health Agency awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $1,140,766 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The award, effective September 1, 2024 through August 31, 2027, will fund a novel mHealth balance assessment and rehabilitation project using computer vision and AI for patients with neurofibromatosis type 2 (NF2). MGH, as the primary research institution, will...
The Defense Health Agency awarded a $321,404 Project Grant to the University of Birmingham under the Military Medical Research and Development program (CFDA 12.420) to support "The Application of AI-Defined Molecular Classifications in Ovarian Cancer". The award, which commenced on September 1, 2024 and runs through August 31, 2026, will enable the University of Birmingham to conduct innovative biomedical research aimed at improving health outcomes for military service members,...